Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19820705 | 1.00 | CHKA (0.81) | CHKACHKB | |
| SCHEMBL19817241 | 0.90 | CHKA (1.00) | CHKACHKB | |
| SCHEMBL19817242 | 0.90 | CHKA (1.00) | CHKACHKB | |
| SCHEMBL19820645 | 0.90 | CHKA (0.77) | CHKACHKB | |
| SCHEMBL21176156 | 0.90 | CHKA (0.77) | CHKACHKB | |
| SCHEMBL19820723 | 0.89 | CHKA (0.72) | CHKACHKB | |
| SCHEMBL19820708 | 0.89 | CHKA (0.72) | CHKACHKB | |
| SCHEMBL19813938 | 0.88 | CHKA (0.86) | CHKACHKB | |
| SCHEMBL19813940 | 0.88 | CHKA (0.86) | CHKACHKB | |
| SCHEMBL19820771 | 0.87 | CHKA (0.74) | CHKACHKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | claimed |
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-06-16 | — | — | US | claimed |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-25 | — | — | US | claimed |
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | disclosed |
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2020-06-16 | — | — | US | disclosed |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683292-B2 | Purine and 3-deazapurine analogues as choline kinase inhibitors | DCK, CHKA, ADK | CHKA 2/4885CHKB 6/4885 |
| US-20190225615-A1 | PURINE AND 3-DEAZAPURINE ANALOGUES AS CHOLINE KINASE INHIBITORS | DCK, CHKA, ADK | CHKA 2/4885CHKB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.